Dose dependent effects of cardiac β 2 adrenoceptor gene therapy

J. Mark Jones, Katrina H. Wilson, Charles Jr Steenbergen, Walter J. Koch, Carmelo A. Milano

Research output: Contribution to journalArticle

Abstract

Adenoviral-mediated gene transfer during cardiopulmonary bypass (CPB) achieves efficient myocardial transgene expression. The optimal vector dose required to produce not only increased β adrenoceptor (βAR) density but, more importantly, enhanced left ventricular (LV) function is unknown. In addition, it is unclear if absent extracardiac expression in preliminary studies represented cardiac specific, as opposed to selective gene delivery, as a consequence of low vector doses. Adenoviral vector encoding the human β 2 adrenoceptor (Adeno-β 2AR) was delivered to cardioplegic arrested hearts of neonatal piglets during CPB in three doses ranging from 5 × 10 11 total viral particles (tvp) to 2 × 10 12 tvp. Control animals received adenoviral vector encoding β galactosidase (Adeno-βgal) or PBS (PBS). LV and liver βAR density and in vivo LV function were assessed 5 days later. Elevated LV βAR density was present after delivery of Adeno-β 2AR at all doses. Piglets which received 5 × 10 11 tvp and 1 × 10 12 tvp Adeno-β 2AR demonstrated enhanced LV dP/dt max but in those receiving 2 × 10 12 tvp LV dP/dt max was unchanged. Moreover, at this higher dose of adenoviral vector the detrimental effects of cardiac inflammation and extracardiac gene overexpression became apparent. Although the highest increase in cardiac βAR density occurred after high-dose Adeno-β 2AR, LV dP/dt max was not enhanced. Moreover, significant extracardiac gene expression was present at this dose, emphasizing the need for careful dose response studies in gene therapy. However, cardiac selective β 2AR overexpression does occur following adenoviral vector delivery during CPB and cardioplegic arrest resulting in enhanced LV dP/dt max.

Original languageEnglish (US)
Pages (from-to)113-120
Number of pages8
JournalJournal of Surgical Research
Volume122
Issue number1
DOIs
StatePublished - Nov 2004
Externally publishedYes

Fingerprint

Genetic Therapy
Adrenergic Receptors
Virion
Cardiopulmonary Bypass
Left Ventricular Function
Galactosidases
Genes
Transgenes
Inflammation
Gene Expression
Liver

Keywords

  • β-adrenergic receptor
  • cardiopulmonary bypass
  • gene therapy
  • hemodynamics
  • surgery

ASJC Scopus subject areas

  • Surgery

Cite this

Dose dependent effects of cardiac β 2 adrenoceptor gene therapy. / Jones, J. Mark; Wilson, Katrina H.; Steenbergen, Charles Jr; Koch, Walter J.; Milano, Carmelo A.

In: Journal of Surgical Research, Vol. 122, No. 1, 11.2004, p. 113-120.

Research output: Contribution to journalArticle

Jones, J. Mark ; Wilson, Katrina H. ; Steenbergen, Charles Jr ; Koch, Walter J. ; Milano, Carmelo A. / Dose dependent effects of cardiac β 2 adrenoceptor gene therapy. In: Journal of Surgical Research. 2004 ; Vol. 122, No. 1. pp. 113-120.
@article{b3801f2a36fe421599c0fbfb357d5e15,
title = "Dose dependent effects of cardiac β 2 adrenoceptor gene therapy",
abstract = "Adenoviral-mediated gene transfer during cardiopulmonary bypass (CPB) achieves efficient myocardial transgene expression. The optimal vector dose required to produce not only increased β adrenoceptor (βAR) density but, more importantly, enhanced left ventricular (LV) function is unknown. In addition, it is unclear if absent extracardiac expression in preliminary studies represented cardiac specific, as opposed to selective gene delivery, as a consequence of low vector doses. Adenoviral vector encoding the human β 2 adrenoceptor (Adeno-β 2AR) was delivered to cardioplegic arrested hearts of neonatal piglets during CPB in three doses ranging from 5 × 10 11 total viral particles (tvp) to 2 × 10 12 tvp. Control animals received adenoviral vector encoding β galactosidase (Adeno-βgal) or PBS (PBS). LV and liver βAR density and in vivo LV function were assessed 5 days later. Elevated LV βAR density was present after delivery of Adeno-β 2AR at all doses. Piglets which received 5 × 10 11 tvp and 1 × 10 12 tvp Adeno-β 2AR demonstrated enhanced LV dP/dt max but in those receiving 2 × 10 12 tvp LV dP/dt max was unchanged. Moreover, at this higher dose of adenoviral vector the detrimental effects of cardiac inflammation and extracardiac gene overexpression became apparent. Although the highest increase in cardiac βAR density occurred after high-dose Adeno-β 2AR, LV dP/dt max was not enhanced. Moreover, significant extracardiac gene expression was present at this dose, emphasizing the need for careful dose response studies in gene therapy. However, cardiac selective β 2AR overexpression does occur following adenoviral vector delivery during CPB and cardioplegic arrest resulting in enhanced LV dP/dt max.",
keywords = "β-adrenergic receptor, cardiopulmonary bypass, gene therapy, hemodynamics, surgery",
author = "Jones, {J. Mark} and Wilson, {Katrina H.} and Steenbergen, {Charles Jr} and Koch, {Walter J.} and Milano, {Carmelo A.}",
year = "2004",
month = "11",
doi = "10.1016/j.jss.2004.06.009",
language = "English (US)",
volume = "122",
pages = "113--120",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Dose dependent effects of cardiac β 2 adrenoceptor gene therapy

AU - Jones, J. Mark

AU - Wilson, Katrina H.

AU - Steenbergen, Charles Jr

AU - Koch, Walter J.

AU - Milano, Carmelo A.

PY - 2004/11

Y1 - 2004/11

N2 - Adenoviral-mediated gene transfer during cardiopulmonary bypass (CPB) achieves efficient myocardial transgene expression. The optimal vector dose required to produce not only increased β adrenoceptor (βAR) density but, more importantly, enhanced left ventricular (LV) function is unknown. In addition, it is unclear if absent extracardiac expression in preliminary studies represented cardiac specific, as opposed to selective gene delivery, as a consequence of low vector doses. Adenoviral vector encoding the human β 2 adrenoceptor (Adeno-β 2AR) was delivered to cardioplegic arrested hearts of neonatal piglets during CPB in three doses ranging from 5 × 10 11 total viral particles (tvp) to 2 × 10 12 tvp. Control animals received adenoviral vector encoding β galactosidase (Adeno-βgal) or PBS (PBS). LV and liver βAR density and in vivo LV function were assessed 5 days later. Elevated LV βAR density was present after delivery of Adeno-β 2AR at all doses. Piglets which received 5 × 10 11 tvp and 1 × 10 12 tvp Adeno-β 2AR demonstrated enhanced LV dP/dt max but in those receiving 2 × 10 12 tvp LV dP/dt max was unchanged. Moreover, at this higher dose of adenoviral vector the detrimental effects of cardiac inflammation and extracardiac gene overexpression became apparent. Although the highest increase in cardiac βAR density occurred after high-dose Adeno-β 2AR, LV dP/dt max was not enhanced. Moreover, significant extracardiac gene expression was present at this dose, emphasizing the need for careful dose response studies in gene therapy. However, cardiac selective β 2AR overexpression does occur following adenoviral vector delivery during CPB and cardioplegic arrest resulting in enhanced LV dP/dt max.

AB - Adenoviral-mediated gene transfer during cardiopulmonary bypass (CPB) achieves efficient myocardial transgene expression. The optimal vector dose required to produce not only increased β adrenoceptor (βAR) density but, more importantly, enhanced left ventricular (LV) function is unknown. In addition, it is unclear if absent extracardiac expression in preliminary studies represented cardiac specific, as opposed to selective gene delivery, as a consequence of low vector doses. Adenoviral vector encoding the human β 2 adrenoceptor (Adeno-β 2AR) was delivered to cardioplegic arrested hearts of neonatal piglets during CPB in three doses ranging from 5 × 10 11 total viral particles (tvp) to 2 × 10 12 tvp. Control animals received adenoviral vector encoding β galactosidase (Adeno-βgal) or PBS (PBS). LV and liver βAR density and in vivo LV function were assessed 5 days later. Elevated LV βAR density was present after delivery of Adeno-β 2AR at all doses. Piglets which received 5 × 10 11 tvp and 1 × 10 12 tvp Adeno-β 2AR demonstrated enhanced LV dP/dt max but in those receiving 2 × 10 12 tvp LV dP/dt max was unchanged. Moreover, at this higher dose of adenoviral vector the detrimental effects of cardiac inflammation and extracardiac gene overexpression became apparent. Although the highest increase in cardiac βAR density occurred after high-dose Adeno-β 2AR, LV dP/dt max was not enhanced. Moreover, significant extracardiac gene expression was present at this dose, emphasizing the need for careful dose response studies in gene therapy. However, cardiac selective β 2AR overexpression does occur following adenoviral vector delivery during CPB and cardioplegic arrest resulting in enhanced LV dP/dt max.

KW - β-adrenergic receptor

KW - cardiopulmonary bypass

KW - gene therapy

KW - hemodynamics

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=7444222294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7444222294&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2004.06.009

DO - 10.1016/j.jss.2004.06.009

M3 - Article

C2 - 15522323

AN - SCOPUS:7444222294

VL - 122

SP - 113

EP - 120

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -